← Leaderboards
Ashley Brown
University Of Florida
$2,797,681
Attributed
$5,595,362
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,934,921 · 2
By mechanism
R01$5,595,362 · 1
P01$2,339,559 · 1
Top collaborators
- George Louis Drusano5 shared
- Jurgen Bernd Bulitta1 shared
- Arnold Louie1 shared
Most similar at University Of Florida
Same institution · by research overlap
- George Louis Drusano$18,475,919
- Arnold Louie$12,883,478
- Sankar Swaminathan$16,219,587
- Michael N. Neely$9,304,264
- Yinzhi Lang$1,261,878
Others in their field
Top investigators on “Success”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$277,058,716
- Lawrence Corey · Fred Hutchinson Cancer Center$274,406,165
- Barton F Haynes · Duke University$260,353,372
Research focus
SuccessMutantPharmaceutical PreparationsStandard Of CareDesignAffectInfectionNovel TherapeuticsRegimenSiteDosageResistanceDoseProgramsClinical TrialsEvaluationMathematical ModelAntiviral TherapyAntiviral ResistanceAntiviral AgentsBiological ModelsAlgorithmsDrug CombinationsCombined Modality Therapy
Grant awards (6)
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is$2,339,559
P01 · FY2025 · AI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,096,497
R01 · FY2018 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,103,751
R01 · FY2017 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,120,190
R01 · FY2016 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,127,672
R01 · FY2015 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,147,252
R01 · FY2014 · AI · contact PI